Table 1.

Hemato-oncologic diagnoses of the study population.

	Entire population		Survival outcome at 1 year (N = 108)				P
			Deceased		Survived
N	112		83		25
Non-hematologic malignancy	89	(79.5)	67	(80.7)	19	(76.0)	0.607
Cancer origin*
Lung	24	(27.0)	21	(31.3)	3	(15.8)	0.182
Head and neck	20	(22.5)	12	(17.9)	6	(31.6)	0.213
Genitourinary tract	20	(22.5)	13	(19.4)	6	(31.6)	0.347
Gastrointestinal tract	14	(15.7)	13	(19.4)	1	(5.3)	0.178
Other	20	(22.5)	17	(25.4)	3	(15.8)	0.542
Disease status*							0.001
Controlled†	52	(58.4)	32	(47.8)	17	(89.5)
Uncontrolled†	37	(41.6)	35	(52.2)	2	(10.5)
Hematologic malignancy	28	(25.0)	20	(24.1)	7	(28.0)	0.693
Cancer histology‡							0.209
Leukemia	15	(53.6)	12	(60.0)	2	(28.6)
Lymphoma or multiple myeloma	13	(46.4)	8	(40.0)	5	(71.4)
Disease status‡							0.58
Controlled†	5	(17.9)	3	(15.0)	2	(28.6)
Uncontrolled†	23	(82.1)	17	(85.0)	5	(71.4)
Double malignancies §	14	(12.5)	13	(15.7)	1	(4.0)	0.181

Data are presented as number (%). *Number (%) among patients with non-hematologic malignancy (n = 89). ^†Disease conditions classified as cure, complete remission, partial remission, or stable disease were considered controlled, while those classified as progressive or newly-diagnosed diseases were considered uncontrolled. In patients with non-hematologic malignancies from two different origins, the disease status was defined as uncontrolled if either one was uncontrolled. ^‡Number (%) among patients with hematologic malignancy (n = 28). ^§Nine patients with solid cancers from two different origins, 4 patients with both solid cancer and hematologic malignancy, and 1 patient with hematologic malignancy and solid cancers from two different origins (triple malignancies).